Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana (EpiDFA)

The justification of this prospective and multicenter study is based on the absence of published data concerning, status epilepticus (SE), a pathology which seems frequent in the French West Indies (FWI) and French Guiana, and whose etiological and prognostic characteristics are often mentioned or assumed but which remain to be demonstrated. The scientific interest lies both in the knowledge of the epidemiology of this pathology and in the identification of the main etiologies, in particular the underlying brain lesions.

The morbidity of SE is significant, associating neurological disorders with impaired consciousness, respiratory, hemodynamic and cardiac rhythm disorders, as well as metabolic disorders such as acidosis. SE-related mortality in the acute phase ranges from 3-40% across studies and regions, while long-term mortality ranges from 17-80% depending on age, cause of SE, comorbidities and the occurrence of complications.

The prognosis of this pathology has however improved in recent years in developed countries or countries with a high level of health system. On the other hand, the morbidity and mortality of SE in the French overseas departments is not known, even if these territories are supposed to be at an equivalent level in terms of health system to that of mainland France.

Study Overview

• Status: Recruiting
• Conditions: Epilepsy; Status Epilepticus
• Intervention / Treatment: Other: Routine care

Detailed Description

Epilepsy is a chronic neurological disease characterized by the occurrence of intermittent seizures, often isolated, but which can progress to status epilepticus (SE) when the seizures are repeated at short intervals without recovery of consciousness. SE is an acute complication that occurs during epileptic disease, but it can also occur outside of known epilepsy, indicative of acute neurological or systemic damage. SE is a neurological emergency, the second after stroke. The incidence of the occurrence of SE is estimated at 12.6 cases per 100,000 person-year, but is widely variable depending on the study region.

The epidemiological, clinical, etiological and prognostic characteristics of epilepsy and SE vary depending on the continent and region, mainly linked to the exposing or favoring factors as well as the socio-economic level of the population, the healthcare offer of the patient health system and accessibility to care for the population.

In France, the management of SE has been codified by Formalized Expert Recommendations (RFE) from learned societies in Emergencies and Resuscitation. The last updated RFE was published in 2018. However, very few studies have been carried out on SE in prehospital or emergencies department. There are no national epidemiological data on SE. To our knowledge, there is no data on the prevalence of SE in the French West Indies (FWI) and French Guiana and even less on the main aetiologies and prognosis of this acute neurological complication.

The interest of this prospective study is to evaluate, through the emergency system, the incidence, the modes of clinical presentation, the etiologies, the therapeutic modalities and finally the prognosis of SE in French overseas departments. This study is of scientific interest for the new knowledge it will bring, because there is no data concerning this relatively common pathology in these regions.

The results of the study would contribute to the improvement of scientific knowledge, to the highlighting of potential particularities and specificities of this pathology in the FWI and French Guiana, and would contribute to improving medical practice and the management of these patients.

• Study Type: Observational
• Enrollment (Estimated): 241

Contacts and Locations

• Study Contact: Name: Florian Negrello, MD; Phone Number: +596 05 96 55 20 15; Email: florian.negrello@chu-martinique.fr
• Study Contact Backup: Name: Papa Gueye, PhD; Email: papa.gueye@chu-martinique.fr

Study Locations

• France
  • French Guiana
    • Cayenne, French Guiana, France, 97306
      • Recruiting
      • Hospital of Cayenne
      • Contact: Jean-Marc Pujo, MD; Email: jean-marc.pujo@ch-cayenne.fr
      • Principal Investigator: Jean-Marc Pujo, MD
      • Sub-Investigator: Hatem Kallel, PhD
  • Guadeloupe
    • Basse-Terre, Guadeloupe, France, 97100
      • Not yet recruiting
      • Hospital of Basse-Terre
      • Contact: Julieta Quesada, MD; Email: julieta.quesada@ch-labasseterre.fr
      • Principal Investigator: Julieta Quesada, MD
    • Pointe-à-Pitre, Guadeloupe, France, 97159
      • Not yet recruiting
      • University Hospital Center of Guadeloupe
      • Contact: Patrick Portecop, MD; Email: patrick.portecop@chu-guadeloupe.fr
      • Principal Investigator: Patrick Portecop, MD
      • Sub-Investigator: Delphine Delta, MD
      • Sub-Investigator: Marc Valette, MD
  • Martinique
    • Fort-de-France, Martinique, France, 97261
      • Recruiting
      • University Hospital Center of Martinique
      • Contact: Yann Mopsus, MSc; Email: yann.mopsus@chu-martinique.fr
      • Principal Investigator: Florian Negrello, MD
      • Sub-Investigator: Papa Gueye, PhD
      • Sub-Investigator: Sylvie Porthault, MD
      • Sub-Investigator: Yannick Brouste, MD
      • Sub-Investigator: Cyrille Chabartier, MD
      • Sub-Investigator: Céline Maisondieu, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients covered for suspected or SE diagnosis

Description

Inclusion Criteria:

• Adult patients (≥ 18 years old) treated for SE by SAMU/SMUR and by emergencies or intensive care in the French West Indies and French Guiana.

• Covered for suspected or SE diagnosis defined by one of the following:

  • a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.
  • a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.
  • a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.
  • an absence-type crisis that lasts longer than 10 to 15 minutes.
  • a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.
  • a coma with an epileptic cause diagnosed on an EEG.
• Patient if he is able to, or representative of the patient in case of incapacity, having given his agreement for the use of his medical data for this research.

Exclusion Criteria:

• Age < 18 years old
• Absence of consent from the patient, or representative to the use of the data for the research.
• Patient whose main residence is not in the department where the study is taking place (vacationer for example).

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Subjects covered for suspected or SE diagnosis; Patients covered for suspected or SE diagnosis defined by one of the following: a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.; a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.; a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.; an absence-type crisis that lasts longer than 10 to 15 minutes.; a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.; a coma with an epileptic cause diagnosed on an EEG.

Other: Routine care; The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge). No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To measure the annual incidence rate of occurrence of status epilepticus (SE) in adults treated by SAMU/SMUR and emergency services in the French West Indies and French Guiana.	The incidence rate of the occurrence of SE expressed per 100,000 person-years.This incidence rate will be calculated by dividing the number of new cases of SE during the 12 months of the inclusion phase of the study by the estimate of the average number of inhabitants aged 18 and over in each region of inclusion.	15 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To describe the epidemiological characteristics of status epilepticus in adults in the French West Indies and French Guiana in terms of patient profiles, associated factors, recurrences, causes and complications.	Characteristics of the patients (age, sex) / Number and percentage of patients with factors associated with SE (alcoholism, drug addiction, precarity, etc.) / Number and percentage of recurrences of SE episodes (antecedent of SE) / Number and percentage of the different causes causing a SE episode / Number and percentage of the different complications during the occurrence of a SE episode.	15 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To describe the neurological evolution 30 days and 90 days after the SE eoisode in adults in the French West Indies and French Guiana.	Number and percentage of patients with an unfavorable neurological evolution according to an assessment using the Modified Rankin Scale (MRS greater than 2) in the adult SE population at day 30 and day 90.	15 months
To measure the mortality rate at day 1, day 30 and day 90 after the onset of SE in adults treated by SAMU/SMUR and emergency services in the French West Indies and French Guiana.	Mortality rate in the adult SE population included in the study on day 1, day 30 and day 90.	15 months

Collaborators and Investigators

• Sponsor: University Hospital Center of Martinique
• Investigators: Principal Investigator: Florian Negrello, MD, University Hospital Center of Martinique

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2022
• Primary Completion (Estimated): October 31, 2024
• Study Completion (Estimated): January 30, 2025

Study Registration Dates

• First Submitted: February 9, 2022
• First Submitted That Met QC Criteria: February 9, 2022
• First Posted (Actual): February 18, 2022

Study Record Updates

• Last Update Posted (Actual): August 23, 2024
• Last Update Submitted That Met QC Criteria: August 22, 2024
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Epilepsy; Epidemiology; Status Epilepticus; Pronostic
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Seizures; Epilepsy; Status Epilepticus
• Other Study ID Numbers: 21_RIPH3-05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No